Kathleen Borthwick's most recent trade in Passage Bio Inc was a trade of 278,386 Employee Stock Option (right to buy) done . Disclosure was reported to the exchange on March 15, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Passage Bio Inc | Kathleen Borthwick | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2025 | 278,386 | 278,386 | - | - | Employee Stock Option (right to buy) | |
| Passage Bio Inc | Kathleen Borthwick | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2025 | 8,000 | 44,466 (0%) | 0% | - | Common Stock | |
| Passage Bio Inc | Kathleen Borthwick | CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2025 | 8,000 | 0 | - | - | Restricted Stock Unit | |
| Passage Bio Inc | Kathleen Borthwick | CFO | Sale of securities on an exchange or to another person at price $ 0.53 per share. | 10 Feb 2025 | 3,183 | 41,283 (0%) | 0% | 0.5 | 1,686 | Common Stock |
| Passage Bio Inc | Kathleen Borthwick | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 227,000 | 227,000 | - | - | Employee Stock Option (right to buy) | |
| Passage Bio Inc | Kathleen Borthwick | SVP, INTERIM CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2024 | 4,000 | 8,000 | - | - | Restricted Stock Unit | |
| Passage Bio Inc | Borthwick Kathleen | SVP, INTERIM CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2024 | 4,000 | 29,936 (0%) | 0% | - | Common Stock | |
| Passage Bio Inc | Borthwick Kathleen | SVP, INTERIM CFO | Sale of securities on an exchange or to another person at price $ 0.97 per share. | 10 Feb 2024 | 1,470 | 28,466 (0%) | 0% | 1.0 | 1,426 | Common Stock |
| Passage Bio Inc | Kathleen Borthwick | SVP, Interim CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2023 | 30,000 | 36,608 (0%) | 0% | - | Common Stock | |
| Passage Bio Inc | Kathleen Borthwick | SVP, Interim CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2023 | 30,000 | 0 | - | - | Restricted Stock Unit | |
| Passage Bio Inc | Kathleen Borthwick | SVP, Interim CFO | Sale of securities on an exchange or to another person at price $ 0.91 per share. | 31 Dec 2023 | 10,672 | 25,936 (0%) | 0% | 0.9 | 9,712 | Common Stock |
| Passage Bio Inc | Kathleen Borthwick | SVP, Interim CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2023 | 20,000 | 20,000 | - | - | Employee Stock Option (right to buy) |